New drug trial aims to keep blood cancers at bay after transplant
NCT ID NCT03286530
Summary
This study is testing whether taking the drug ruxolitinib after a stem cell transplant can help prevent cancer from returning in older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The trial involves 64 participants aged 60-80 who have achieved remission and will receive a stem cell transplant. Researchers want to see if ruxolitinib, taken as ongoing maintenance therapy, improves survival by reducing both cancer relapse and transplant complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
Medical College of Wisconsin
Wauwatosa, Wisconsin, 53226, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
Vanderbilt University
Nashville, Tennessee, 37235, United States
-
Washington University
St Louis, Missouri, 63130, United States
Conditions
Explore the condition pages connected to this study.